查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1500161

过敏诊断和治疗市场 - 全球行业规模、份额、趋势、机会和预测，按类型、过敏原类型、测试类型、地区和竞争细分，2019-2029F

Allergy Diagnostics and Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type, By Allergen Type, By Test Type, By Region and Competition, 2019-2029F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

2023 年全球过敏诊断和治疗市场估值为 313.6 亿美元，预计在预测期内稳定成长，到 2029 年复合年增长率为 7.89%。医疗保健产业，旨在诊断和治疗全球过敏性疾病。过敏是一个重大的健康问题，影响着各个年龄层和地理区域的数百万人。该市场涵盖广泛的诊断工具和治疗干预措施，旨在管理各种过敏性疾病，包括过敏性鼻炎、气喘、食物过敏、湿疹等。该市场受到几个关键因素的推动，包括过敏盛行率的上升、认识和诊断率的提高、诊断技术的进步以及新型疗法的开发。

市场概况
预测期 2025-2029
2023 年市场规模 313.6亿美元
2029 年市场规模 481.6亿美元
2024-2029 年复合年增长率 7.89%
成长最快的细分市场 诊断
最大的市场 北美洲

全球过敏诊断和治疗市场的主要驱动力之一是过敏性疾病盛行率的不断上升。都市化、环境污染、生活型态和饮食习惯的改变等因素导致全球过敏发生率不断上升。因此，对准确有效的诊断方法来识别过敏原和过敏触发因素的需求不断增长，从而推动了市场内诊断领域的成长。此外，人们越来越认识到过敏是一个重要的公共卫生问题，这促使人们努力改善诊断和治疗的机会，进一步推动市场扩张。

诊断技术的进步在塑造过敏诊断领域发挥了至关重要的作用。皮肤点刺测试和血液检查等传统方法仍然是过敏诊断的基本工具，但市场已经见证了创新技术的出现，包括分子诊断、免疫分析和即时检测。这些技术具有更高的灵敏度和特异性、更快的周转时间以及检测更广泛的过敏原的能力等优点，从而提高了过敏诊断的准确性和效率。

全球过敏诊断和治疗市场的治疗部分涵盖多种治疗方案，旨在管理过敏症状和改善患者的生活品质。抗组织胺、皮质类固醇、白三烯受体拮抗剂和免疫调节剂等药物干预措施构成了过敏治疗的基石，可缓解打喷嚏、瘙痒、鼻塞和发炎等症状。近年来，人们越来越重视开发针对参与过敏反应的免疫系统特定成分的生物疗法，为患有严重或难治性过敏的患者提供个人化和有针对性的治疗方法。

主要市场驱动因素

过敏性疾病盛行率上升

提高认识和诊断率

生物技术和製造工艺的进步

主要市场挑战

诊断不足及误诊

获得医疗服务的机会有限

过敏性疾病的复杂性

主要市场趋势

诊断技术的进步

专注精准医疗

细分市场洞察

类型洞察

过敏原型见解

区域洞察

目录

第 1 章：产品概述

第 2 章：研究方法

第 3 章：执行摘要

第 4 章：客户之声

第 5 章：全球过敏诊断与治疗市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按类型（诊断、治疗）
    • 依过敏原类型（食物、吸入、药物、其他过敏原）
    • 依测试类型（体内测试、体外测试）
    • 按地区
    • 按公司划分 (2023)
  • 市场地图
    • 按类型
    • 按过敏原类型
    • 按测试类型
    • 按地区

第 6 章：亚太地区过敏诊断与治疗市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按类型
    • 按过敏原类型
    • 按测试类型
    • 按国家/地区
  • 亚太地区：国家分析
    • 中国
    • 印度
    • 澳洲
    • 日本
    • 韩国

第 7 章：欧洲过敏诊断与治疗市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按类型
    • 按过敏原类型
    • 按测试类型
    • 按国家/地区
  • 欧洲：国家分析
    • 法国
    • 德国
    • 西班牙
    • 义大利
    • 英国

第 8 章：北美过敏诊断与治疗市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按类型
    • 按过敏原类型
    • 按测试类型
    • 按国家/地区
  • 北美：国家分析
    • 美国
    • 墨西哥
    • 加拿大

第 9 章：南美洲过敏诊断与治疗市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按类型
    • 按过敏原类型
    • 按测试类型
    • 按国家/地区
  • 南美洲：国家分析
    • 巴西
    • 阿根廷
    • 哥伦比亚

第 10 章：中东和非洲过敏诊断和治疗市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按类型
    • 按过敏原类型
    • 按测试类型
    • 按国家/地区
  • MEA：国家分析
    • 南非
    • 沙乌地阿拉伯
    • 阿联酋
    • 埃及

第 11 章：市场动态

  • 司机
  • 挑战

第 12 章：市场趋势与发展

  • 最近的发展
  • 产品发布
  • 併购

第 13 章：全球过敏诊断与治疗市场：SWOT 分析

第 14 章：波特的五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的力量
  • 客户的力量
  • 替代产品的威胁

第15章：竞争格局

  • Thermo Fisher Scientific, Inc.
  • R-Biopharm AG
  • DASIT Group SPA
  • AGILUS DIAGNOSTICS LTD.
  • AESKU.GROUP GmbH
  • bioMerieux SA
  • Siemens Healthineers AG
  • STALLERGENES GREER International AG
  • HYCOR Biomedical, LLC
  • Minaris Medical America, Inc.

第 16 章：策略建议

第17章调查会社について・免责事项

简介目录
Product Code: 23905

Global Allergy Diagnostics and Therapeutics Market was valued at USD 31.36 Billion in 2023 and is anticipated to project steady growth in the forecast period with a CAGR of 7.89% through 2029. The Global Allergy Diagnostics and Therapeutics Market is a dynamic and rapidly evolving sector within the healthcare industry, aimed at diagnosing and treating allergic diseases worldwide. Allergies represent a significant health concern, affecting millions of individuals across all age groups and geographical regions. This market encompasses a wide range of diagnostic tools and therapeutic interventions designed to manage various allergic conditions, including allergic rhinitis, asthma, food allergies, eczema, and others. The market is driven by several key factors, including the rising prevalence of allergies, increasing awareness and diagnosis rates, advancements in diagnostic technologies, and the development of novel therapeutics.

Market Overview
Forecast Period2025-2029
Market Size 2023USD 31.36 Billion
Market Size 2029USD 48.16 Billion
CAGR 2024-20297.89%
Fastest Growing SegmentDiagnostics
Largest MarketNorth America

One of the primary drivers of the Global Allergy Diagnostics and Therapeutics Market is the escalating prevalence of allergic diseases. Factors such as urbanization, environmental pollution, changes in lifestyle, and dietary habits have contributed to the rising incidence of allergies worldwide. As a result, there is a growing demand for accurate and efficient diagnostic methods to identify allergens and allergic triggers, driving the growth of the diagnostics segment within the market. Additionally, the increasing recognition of allergies as a significant public health issue has spurred efforts to improve access to diagnosis and treatment, further fueling market expansion.

Advancements in diagnostic technologies have played a crucial role in shaping the landscape of allergy diagnostics. Traditional methods such as skin prick tests and blood tests remain foundational tools for allergy diagnosis, but the market has witnessed the emergence of innovative technologies, including molecular diagnostics, immunoassays, and point-of-care tests. These technologies offer advantages such as greater sensitivity and specificity, faster turnaround times, and the ability to detect a broader range of allergens, thus enhancing the accuracy and efficiency of allergy diagnosis.

The therapeutics segment of the Global Allergy Diagnostics and Therapeutics Market encompasses a diverse array of treatment options aimed at managing allergic symptoms and improving patients' quality of life. Pharmacological interventions such as antihistamines, corticosteroids, leukotriene receptor antagonists, and immunomodulators form the cornerstone of allergy treatment, providing relief from symptoms such as sneezing, itching, nasal congestion, and inflammation. In recent years, there has been a growing emphasis on the development of biologic therapies targeting specific components of the immune system involved in allergic responses, offering personalized and targeted treatment approaches for patients with severe or refractory allergies.

Key Market Drivers

Rising Prevalence of Allergic Diseases

The rising prevalence of allergic diseases is a significant driver behind the growth of the Global Allergy Diagnostics and Therapeutics Market. Allergic conditions, such as allergic rhinitis, asthma, food allergies, and eczema, have become increasingly common worldwide, affecting millions of individuals across all age groups and geographical regions. Several factors contribute to this escalating prevalence, including environmental factors, changes in lifestyle, and dietary habits.

Environmental pollution, including air pollution, indoor allergens, and exposure to pollutants such as pollen and mold, plays a crucial role in triggering allergic responses. Urbanization and industrialization have led to increased levels of air pollution, exacerbating respiratory allergies such as allergic rhinitis and asthma. Similarly, indoor allergens such as dust mites, pet dander, and mold thrive in modern living environments, contributing to the development and exacerbation of allergic conditions.

Changes in lifestyle and dietary habits have also been linked to the rising prevalence of allergic diseases. Westernized diets high in processed foods, sugar, and additives have been associated with an increased risk of food allergies and sensitivities. Additionally, reduced exposure to outdoor environments and microbial diversity, often attributed to urban living and excessive hygiene practices, may contribute to the development of allergic conditions by altering immune system development and function.

The increasing prevalence of allergic diseases has led to a growing burden on healthcare systems globally, driving demand for effective diagnostic tools and therapeutic interventions. Healthcare providers are facing greater challenges in accurately diagnosing allergic conditions and implementing appropriate treatment strategies to manage symptoms and improve patients' quality of life.

In response to this growing demand, the Global Allergy Diagnostics and Therapeutics Market has witnessed significant advancements in diagnostic technologies and therapeutic options. Innovative diagnostic tools, including molecular diagnostics, immunoassays, and point-of-care tests, offer improved accuracy and efficiency in identifying allergic triggers and guiding treatment decisions. Similarly, the development of novel therapeutic modalities, such as biologic therapies and allergen immunotherapy, provides personalized and targeted treatment approaches for patients with severe or refractory allergies.

Increasing Awareness and Diagnosis Rates

The Global Allergy Diagnostics and Therapeutics Market is experiencing a significant boost from increasing awareness and diagnosis rates of allergic diseases worldwide. Awareness campaigns, education initiatives, and greater understanding among both healthcare professionals and the general population have led to heightened recognition of allergic conditions and their impact on individuals' health and well-being. One of the primary factors driving increased awareness is the growing prevalence of allergic diseases. Allergies, including allergic rhinitis, asthma, food allergies, and eczema, are becoming more common across all age groups and geographical regions. As more people experience allergic symptoms or witness them in family members or peers, there is a natural inclination to seek medical attention and explore potential causes and treatment options.

Also, the media and internet have played a crucial role in disseminating information about allergies and raising public awareness. Health-related websites, social media platforms, and online forums provide a platform for individuals to share their experiences, seek advice, and access reliable information about allergic diseases and their management. This increased accessibility to information empowers individuals to recognize and address allergic symptoms promptly, leading to earlier diagnosis and intervention.

Healthcare professionals also play a vital role in increasing awareness and facilitating timely diagnosis of allergic conditions. Continuous medical education programs, conferences, and seminars educate healthcare providers about the latest developments in allergy diagnostics and therapeutics, enabling them to accurately identify and manage allergic diseases in their patients. Additionally, guidelines and protocols for allergy diagnosis and treatment help standardize practices and ensure consistent quality of care across healthcare settings.

As awareness of allergic diseases grows, there is a corresponding increase in diagnosis rates as more individuals seek medical evaluation for their symptoms. Early diagnosis is essential for effective management of allergic conditions, as it allows for prompt initiation of appropriate treatment and preventive measures. Timely diagnosis also helps prevent complications and reduces the burden on healthcare systems by minimizing the need for emergency care and hospitalizations.

Advancements in Biotechnology and Manufacturing Processes

Advancements in diagnostic technologies are playing a pivotal role in boosting the Global Allergy Diagnostics and Therapeutics Market. These innovations are transforming the landscape of allergy diagnosis by enhancing accuracy, sensitivity, and efficiency, thereby enabling healthcare providers to effectively identify allergens and tailor treatment plans to individual patients' needs. Traditional methods of allergy diagnosis, such as skin prick tests and blood tests, remain valuable tools in clinical practice. However, advancements in diagnostic technologies have introduced a new era of precision and convenience in allergy testing. Molecular diagnostics, for instance, allow for the detection of specific genetic markers associated with allergic conditions, providing a deeper understanding of patients' immune responses, and guiding personalized treatment decisions.

Immunoassays represent another area of innovation in allergy diagnostics. These assays utilize antibodies to detect and quantify allergen-specific antibodies (IgE) in patient samples, offering high sensitivity and specificity in identifying allergic triggers. Immunoassays can be performed using various platforms, including enzyme-linked immunosorbent assays (ELISA) and fluorescent immunoassays (FIA), allowing for flexibility and scalability in allergy testing.

Point-of-care tests (POCTs) have emerged as a valuable tool for allergy diagnosis, particularly in primary care settings and remote or underserved areas. POCTs offer rapid results, often within minutes, enabling immediate identification of allergic sensitivities and facilitating timely intervention. These portable and user-friendly devices empower healthcare providers to perform allergy testing conveniently at the point of care, without the need for specialized laboratory equipment or extensive training.

The integration of digital technologies into allergy diagnostics has further expanded the capabilities of diagnostic platforms. Electronic health records (EHRs), telemedicine platforms, and mobile applications enable seamless communication and data sharing between patients and healthcare providers, facilitating remote monitoring and management of allergic diseases. Moreover, artificial intelligence (AI) and machine learning algorithms can analyze large datasets to identify patterns and correlations in allergic responses, leading to more accurate diagnosis and prediction of treatment outcomes.

Key Market Challenges

Underdiagnoses and Misdiagnosis

One of the primary challenges in the allergy diagnostics and therapeutics market is underdiagnosis and misdiagnosis of allergic diseases. Many individuals with allergic symptoms may not seek medical evaluation, leading to undetected cases. Moreover, misdiagnosis can occur due to overlapping symptoms with other conditions or inadequate diagnostic tools, resulting in inappropriate treatment and disease management.

Limited Access to Healthcare Services

Access to allergy diagnostics and therapeutics is not uniform globally, with disparities in healthcare infrastructure, resources, and expertise contributing to limited access in certain regions. Rural and underserved areas may lack specialized allergy clinics, diagnostic laboratories, and trained healthcare professionals, leading to delayed diagnosis and suboptimal treatment for patients with allergic diseases.

Complexity of Allergic Diseases

Allergic diseases are heterogeneous and multifactorial, presenting challenges in diagnosis and treatment. The complexity of allergic conditions, including the diverse range of allergens and underlying immunological mechanisms involved, can make accurate diagnosis and targeted therapy challenging. Additionally, comorbidities and overlapping symptoms further complicate disease management, requiring a comprehensive and individualized approach to care.

Key Market Trends

Advancements in Diagnostic Technologies

Advancements in diagnostic technologies are revolutionizing the landscape of the Global Allergy Diagnostics and Therapeutics Market. These technological innovations are enhancing the accuracy, efficiency, and accessibility of allergy diagnosis, thereby driving market growth, and improving patient outcomes. Traditional methods of allergy diagnosis, such as skin prick tests and blood tests, have been valuable tools in clinical practice. However, advancements in diagnostic technologies have introduced a new era of precision and convenience in allergy testing. Molecular diagnostics, for instance, allow for the detection of specific genetic markers associated with allergic conditions, providing insights into patients' immune responses, and guiding personalized treatment decisions.

Immunoassays represent another significant advancement in allergy diagnostics. These assays utilize antibodies to detect and quantify allergen-specific antibodies (IgE) in patient samples, offering high sensitivity and specificity in identifying allergic triggers. Immunoassays can be performed using various platforms, including enzyme-linked immunosorbent assays (ELISA) and fluorescent immunoassays (FIA), allowing for flexibility and scalability in allergy testing.

Point-of-care tests (POCTs) have emerged as a game-changer in allergy diagnosis, particularly in primary care settings and remote or underserved areas. POCTs provide rapid results, often within minutes, enabling immediate identification of allergic sensitivities and facilitating timely intervention. These portable and user-friendly devices empower healthcare providers to perform allergy testing conveniently at the point of care, without the need for specialized laboratory equipment or extensive training.

The integration of digital technologies into allergy diagnostics has further expanded the capabilities of diagnostic platforms. Electronic health records (EHRs), telemedicine platforms, and mobile applications enable seamless communication and data sharing between patients and healthcare providers, facilitating remote monitoring and management of allergic diseases. Additionally, artificial intelligence (AI) and machine learning algorithms can analyze large datasets to identify patterns and correlations in allergic responses, leading to more accurate diagnosis and prediction of treatment outcomes.

Focus on Precision Medicine

The focus on precision medicine is significantly boosting the Global Allergy Diagnostics and Therapeutics Market, transforming the landscape of allergy diagnosis and treatment. Precision medicine, also known as personalized medicine, involves tailoring medical interventions to individual patient characteristics, including genetic makeup, environmental factors, and lifestyle considerations. This approach enables healthcare providers to deliver targeted and effective treatments while minimizing adverse effects and optimizing patient outcomes. In the realm of allergy diagnostics, precision medicine has led to advancements in molecular profiling, biomarker identification, and genetic testing. These tools provide insights into patients' immune responses, allergic sensitivities, and predisposition to allergic diseases, allowing for more accurate and comprehensive allergy diagnosis. By analyzing specific genetic markers and immune signatures, healthcare providers can identify individualized allergic triggers and develop personalized treatment plans tailored to each patient's unique profile.

Precision medicine also extends to the field of allergy therapeutics, where innovative treatment approaches are being developed to target underlying disease mechanisms and pathways. Biologic therapies, for example, specifically target key mediators of allergic inflammation, offering a novel treatment option for patients with severe or refractory allergies. These biologic agents provide targeted and personalized treatment approaches, leading to improved symptom control, reduced reliance on systemic corticosteroids, and enhanced quality of life for patients with allergic diseases.

Additionally, precision medicine enables healthcare providers to optimize allergen immunotherapy (AIT), a cornerstone of allergy treatment. By identifying specific allergens to which patients are sensitized and tailoring immunotherapy formulations accordingly, precision medicine enhances treatment efficacy and safety. Personalized AIT regimens result in improved symptom relief, reduced treatment duration, and enhanced patient satisfaction, driving market growth and adoption of immunotherapy as a mainstream treatment option.

The integration of digital health technologies and artificial intelligence (AI) further enhances the precision medicine approach in allergy diagnostics and therapeutics. Electronic health records (EHRs), telemedicine platforms, and mobile applications facilitate data collection, analysis, and sharing, enabling seamless communication between patients and healthcare providers. AI algorithms analyze large datasets to identify patterns, correlations, and predictive markers in allergic responses, guiding treatment decisions and optimizing patient care. The focus on precision medicine is driving innovation, growth, and transformation in the Global Allergy Diagnostics and Therapeutics Market. By embracing personalized approaches to allergy diagnosis and treatment, healthcare providers can deliver more effective, efficient, and patient-centered care, ultimately improving outcomes and quality of life for individuals affected by allergic diseases.

Segmental Insights

Type Insights

Based on Type, Therapeutics have emerged as the dominating segment in the Global Allergy Diagnostics and Therapeutics Market in 2023. The increasing prevalence of allergic conditions globally has spurred a heightened demand for efficacious treatment options. With a growing number of individuals being diagnosed with allergies, there arises a pressing need for therapeutics capable of effectively mitigating symptoms and enhancing quality of life. Innovations in medical research and technology have paved the way for the development of more precise and effective allergy therapeutics. These advancements encompass novel formulations of drugs, biologic treatments, and immunotherapy strategies that specifically target the underlying mechanisms of allergic reactions. Healthcare providers are increasingly acknowledging the significance of personalized treatment approaches in allergy management. This shift has resulted in the adoption of tailored therapeutic protocols tailored to individual patient profiles, considering factors such as allergy type and severity, concurrent medical conditions, and treatment response.

Allergen Type Insights

Based on Allergen Type, Inhaled have emerged as the dominating segment in the Global Allergy Diagnostics and Therapeutics Market in 2023. This dominance is primarily due to the widespread prevalence of respiratory allergies triggered by inhaled allergens such as pollen, dust mites, pet dander, mold spores, and air pollutants. Respiratory allergies, including allergic rhinitis and asthma, affect millions of individuals worldwide, contributing significantly to the overall burden of allergic diseases. Inhaled allergens are particularly pervasive in urban environments, where environmental pollution and exposure to indoor allergens are common, exacerbating allergic symptoms and respiratory conditions.

Regional Insights

Based on Region, North America have emerged as the dominating region in the Global Allergy Diagnostics and Therapeutics Market in 2023. North America boasts advanced healthcare infrastructure and a well-established healthcare system, characterized by high levels of accessibility, quality of care, and technological innovation. This facilitates early detection, accurate diagnosis, and comprehensive management of allergic diseases, driving market growth in the region.

Key Market Players

Thermo Fisher Scientific, Inc.

R-Biopharm AG

DASIT Group SPA

AGILUS DIAGNOSTICS LTD.

AESKU.GROUP GmbH

bioMerieux SA

Siemens Healthineers AG

STALLERGENES GREER International AG

HYCOR Biomedical, LLC

Minaris Medical America, Inc.

Report Scope:

In this report, the Global Allergy Diagnostics and Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Allergy Diagnostics and Therapeutics Market, By Type:

    Diagnostics Therapeutics

Allergy Diagnostics and Therapeutics Market, By Allergen Type:

    Food Inhaled Drug Other Allergens

Allergy Diagnostics and Therapeutics Market, By Test Type:

    Vivo Test Vitro Test

Allergy Diagnostics and Therapeutics Market, By Region:

    North America
    • United States
    • Canada
    • Mexico
    Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
    Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    South America
    • Brazil
    • Argentina
    • Colombia
    Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Egypt

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Allergy Diagnostics and Therapeutics Market.

Available Customizations:

Global Allergy Diagnostics and Therapeutics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Allergy Diagnostics and Therapeutics Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type (Diagnostics, Therapeutics)
    • 5.2.2. By Allergen Type (Food, Inhaled, Drug, Other Allergens)
    • 5.2.3. By Test Type (vivo Test, vitro Test)
    • 5.2.4. By Region
    • 5.2.5. By Company (2023)
  • 5.3. Market Map
    • 5.3.1. By Type
    • 5.3.2. By Allergen Type
    • 5.3.3. By Test Type
    • 5.3.4. By Region

6. Asia Pacific Allergy Diagnostics and Therapeutics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type
    • 6.2.2. By Allergen Type
    • 6.2.3. By Test Type
    • 6.2.4. By Country
  • 6.3. Asia Pacific: Country Analysis
    • 6.3.1. China Allergy Diagnostics and Therapeutics Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Type
        • 6.3.1.2.2. By Allergen Type
        • 6.3.1.2.3. By Test Type
    • 6.3.2. India Allergy Diagnostics and Therapeutics Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Type
        • 6.3.2.2.2. By Allergen Type
        • 6.3.2.2.3. By Test Type
    • 6.3.3. Australia Allergy Diagnostics and Therapeutics Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Type
        • 6.3.3.2.2. By Allergen Type
        • 6.3.3.2.3. By Test Type
    • 6.3.4. Japan Allergy Diagnostics and Therapeutics Market Outlook
      • 6.3.4.1. Market Size & Forecast
        • 6.3.4.1.1. By Value
      • 6.3.4.2. Market Share & Forecast
        • 6.3.4.2.1. By Type
        • 6.3.4.2.2. By Allergen Type
        • 6.3.4.2.3. By Test Type
    • 6.3.5. South Korea Allergy Diagnostics and Therapeutics Market Outlook
      • 6.3.5.1. Market Size & Forecast
        • 6.3.5.1.1. By Value
      • 6.3.5.2. Market Share & Forecast
        • 6.3.5.2.1. By Type
        • 6.3.5.2.2. By Allergen Type
        • 6.3.5.2.3. By Test Type

7. Europe Allergy Diagnostics and Therapeutics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By Allergen Type
    • 7.2.3. By Test Type
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France Allergy Diagnostics and Therapeutics Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
        • 7.3.1.2.2. By Allergen Type
        • 7.3.1.2.3. By Test Type
    • 7.3.2. Germany Allergy Diagnostics and Therapeutics Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
        • 7.3.2.2.2. By Allergen Type
        • 7.3.2.2.3. By Test Type
    • 7.3.3. Spain Allergy Diagnostics and Therapeutics Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Type
        • 7.3.3.2.2. By Allergen Type
        • 7.3.3.2.3. By Test Type
    • 7.3.4. Italy Allergy Diagnostics and Therapeutics Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Type
        • 7.3.4.2.2. By Allergen Type
        • 7.3.4.2.3. By Test Type
    • 7.3.5. United Kingdom Allergy Diagnostics and Therapeutics Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Type
        • 7.3.5.2.2. By Allergen Type
        • 7.3.5.2.3. By Test Type

8. North America Allergy Diagnostics and Therapeutics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By Allergen Type
    • 8.2.3. By Test Type
    • 8.2.4. By Country
  • 8.3. North America: Country Analysis
    • 8.3.1. United States Allergy Diagnostics and Therapeutics Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By Allergen Type
        • 8.3.1.2.3. By Test Type
    • 8.3.2. Mexico Allergy Diagnostics and Therapeutics Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By Allergen Type
        • 8.3.2.2.3. By Test Type
    • 8.3.3. Canada Allergy Diagnostics and Therapeutics Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By Allergen Type
        • 8.3.3.2.3. By Test Type

9. South America Allergy Diagnostics and Therapeutics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By Allergen Type
    • 9.2.3. By Test Type
    • 9.2.4. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Allergy Diagnostics and Therapeutics Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By Allergen Type
        • 9.3.1.2.3. By Test Type
    • 9.3.2. Argentina Allergy Diagnostics and Therapeutics Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By Allergen Type
        • 9.3.2.2.3. By Test Type
    • 9.3.3. Colombia Allergy Diagnostics and Therapeutics Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By Allergen Type
        • 9.3.3.2.3. By Test Type

10. Middle East and Africa Allergy Diagnostics and Therapeutics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By Allergen Type
    • 10.2.3. By Test Type
    • 10.2.4. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Allergy Diagnostics and Therapeutics Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type
        • 10.3.1.2.2. By Allergen Type
        • 10.3.1.2.3. By Test Type
    • 10.3.2. Saudi Arabia Allergy Diagnostics and Therapeutics Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type
        • 10.3.2.2.2. By Allergen Type
        • 10.3.2.2.3. By Test Type
    • 10.3.3. UAE Allergy Diagnostics and Therapeutics Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type
        • 10.3.3.2.2. By Allergen Type
        • 10.3.3.2.3. By Test Type
    • 10.3.4. Egypt Allergy Diagnostics and Therapeutics Market Outlook
      • 10.3.4.1. Market Size & Forecast
        • 10.3.4.1.1. By Value
      • 10.3.4.2. Market Share & Forecast
        • 10.3.4.2.1. By Type
        • 10.3.4.2.2. By Allergen Type
        • 10.3.4.2.3. By Test Type

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Developments
  • 12.2. Product Launches
  • 12.3. Mergers & Acquisitions

13. Global Allergy Diagnostics and Therapeutics Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Product

15. Competitive Landscape

  • 15.1. Thermo Fisher Scientific, Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Company Snapshot
    • 15.1.3. Products & Services
    • 15.1.4. Financials (In case of listed)
    • 15.1.5. Recent Developments
    • 15.1.6. Key Personnel Details
    • 15.1.7. SWOT Analysis
  • 15.2. R-Biopharm AG
  • 15.3. DASIT Group SPA
  • 15.4. AGILUS DIAGNOSTICS LTD.
  • 15.5. AESKU.GROUP GmbH
  • 15.6. bioMerieux SA
  • 15.7. Siemens Healthineers AG
  • 15.8. STALLERGENES GREER International AG
  • 15.9. HYCOR Biomedical, LLC
  • 15.10. Minaris Medical America, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer